Neuroblastoma-targeted Anticancer Drug Delivery
نویسندگان
چکیده
Neuroblastoma (NB) is the most common solid tumor in pediatric cases. NB accounts for about 8% of malignancies patients younger than 15 years, and since 50% newly diagnosed cases metastasize to regional lymph nodes, bone marrow, bone, liver, skin, disease usually its late stages. Overexpression N-MYC, which characterized by poor prognosis NB, changes progression course treatment. Targeting these pathways may be a treatment option mTOR AURKA interact with N-MYC directly cause protein stabilization. The widespread use conventional chemotherapeutics has some limitations associated their side effects bioavailability drugs. New therapeutic approaches have focused on nanoparticle (NP) -based therapies, chemoimmunoagents form many NPs are being tried NB. Here, we review new that would help treat
منابع مشابه
Peptide targeted lipid nanoparticles for anticancer drug delivery.
Encapsulating anticancer drugs in nanoparticles has proven to be an effective mechanism to alter the pharmacokinetic and pharmacodynamic profiles of the drugs, leading to clinically useful cancer therapeutics like Doxil and DaunoXome. Underdeveloped tumor vasculature and lymphatics allow these first-generation nanoparticles to passively accumulate within the tumor, but work to create the next-g...
متن کاملTargeted cytokine delivery to neuroblastoma.
The aim of this study was to construct a fusion protein from the cytokine granulocyte/macrophage colony-stimulating factor (GM-CSF) and a single-chain Fv fragment (scFv D29) and to investigate its potential to activate cells of the immune system against neuroblastoma cells expressing neural cell adhesion molecule (NCAM). Mammalian cell expression of the scFv D29-GM-CSF fusion protein was compar...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ?zmir Dr.Behçet Uz çocuk hastanesi dergisi
سال: 2021
ISSN: ['2146-2372', '1309-9566']
DOI: https://doi.org/10.5222/buchd.2021.04206